# Nebivolol

Drug · id `cardio:nebivolol` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Bystolic

Browse, organ or system: Heart  
Browse, condition area: High blood pressure  

## In plain language

Nebivolol is a beta-blocker taken by mouth. The US label read, for Bystolic, lists one use: the treatment of hypertension, to lower blood pressure.

## Technical summary

RxNorm ingredient 31555; UNII JGS34J7L9I. The label names the substance as nebivolol hydrochloride, so UNII JGS34J7L9I is the UNII of the hydrochloride salt and is a broad match. MeSH descriptor D000068577 is Nebivolol. Class: beta-Adrenergic Blocker (FDA established pharmacologic class, RxClass). The label read is the Allergan, Inc. label for BYSTOLIC (nebivolol hydrochloride), application NDA021742, effective 2024-08-01 in openFDA. Other nebivolol labels in openFDA, from generic sponsors, were not read. This page records label indications and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: People for whom the US label of nebivolol (Bystolic) lists an indication: hypertension

Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The label does not state an age range in the passage read.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passage read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of BYSTOLIC (nebivolol hydrochloride), in the Allergan, Inc. version dated 2024-08-01 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The label does not state an age range in the passage read.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passage read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-08
- Sources:
  1. Supports: openFDA drug label record for BYSTOLIC (nebivolol hydrochloride), Allergan, Inc. label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id 8b8ad213-1dc8-454e-a524-075685c0e1a8 (manufacturer Allergan, Inc., application NDA021742), returned on 2026-11-08. The label text is dated 2024-08-01 (effective\_time). Other openFDA records of nebivolol labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%228b8ad213-1dc8-454e-a524-075685c0e1a8%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1. INDICATIONS AND USAGE. Retrieved 2026-11-08T20:37:15Z. Source state: Current. Version fingerprint: 272454333965f93512f2cc1866c29f068170de6a24c0b87238d21dba3f07fdef.
     How it applies: The label sentences that give the indications named in the statement, each quoted in the research quote table.
  2. Background: openFDA drug label record for BYSTOLIC (nebivolol hydrochloride), Allergan, Inc. label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id 8b8ad213-1dc8-454e-a524-075685c0e1a8 (manufacturer Allergan, Inc., application NDA021742), returned on 2026-11-08. The label text is dated 2024-08-01 (effective\_time). Other openFDA records of nebivolol labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%228b8ad213-1dc8-454e-a524-075685c0e1a8%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-08T20:37:15Z. Source state: Current. Version fingerprint: 272454333965f93512f2cc1866c29f068170de6a24c0b87238d21dba3f07fdef.
     How it applies: Effective date of the label text read, 20240801.

## Connected pages

- Nebivolol is a beta-adrenergic blocker (FDA established pharmacologic class in RxClass): Beta-blockers (drug class) (`cardio:beta-blockers`)
- FDA label lists hypertension as an indication: Hypertension (high blood pressure) (`core:hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-nebivolol-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 2 registry products
- 6 registry trials

## Provenance

Content hash: df4cc2591bc44831f9e9406b778f2108f4b8fd17d652d888c7c10c41486e36cd
Last substantive edit: 2026-11-08
Evidence last checked: 2026-11-08
